Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes
| David Rosenstein | Sat, Oct 3, 10:03 AM (2 days ago) | ||
to me | |||
Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes | MedPage Today
October 5, 2026
What is interesting to know is that diabetics consistently lose less weight on GLP one medication’s than non-diabetics. In this trial, the diabetics lost 18% body mass on the maximum dose yet in other trials, they lost between 25 and 28% body mass.
No one has really identified why this is, but this is not unique to Retatrutide. In fact most, if not all of the GLP one drugs have the same results.
- n
As you can see, there is a substantial amount of data, confirming the discrepancy and weight loss between diabetics and non-diabetics
There are potential reasons why this is and a few are listed below
Loss of glycosuric calorie dumping (strongest candidate). Uncontrolled diabetics spill large amounts of glucose in the urine — potentially hundreds of kcal/day. A non-diabetic has no such leak. When a GLP-1 agonist lowers glucose below the renal threshold, that urinary caloric loss stops, so the diabetic is effectively “reclaiming” calories at the same time the drug is suppressing intake. The net energy deficit is therefore smaller than in a non-diabetic, where every appetite-driven calorie reduction translates directly to deficit. This elegantly explains why higher baseline HbA1c predicts less weight loss on meta-regression — the sicker the glucose control at baseline, the bigger the buffer being removed.
2. Hyperinsulinemia as an anabolic headwind. Type 2 diabetics carry chronic compensatory hyperinsulinemia and insulin resistance. Insulin is the body’s dominant fat-storage signal: it drives lipogenesis and suppresses lipolysis. A GLP-1 agonist creating a modest appetite-driven deficit is working against a persistently high anabolic/fat-sparing hormonal tone that the non-diabetic simply does not have.
3. Blunted incretin responsiveness. There is reason to suspect the diabetic GLP-1 receptor axis is itself less responsive — the native incretin effect is known to be impaired in T2D, and insulin resistance may dampen central GLP-1 signaling on satiety circuits. If the target pathway is partially desensitized, the same drug dose yields less appetite suppression.
4. Pharmacologic sabotage from the rest of the regimen. Insulin, sulfonylureas, and beta-blockers all promote weight gain, and fear of hypoglycemia discourages aggressive caloric restriction. This is real but clearly not the whole story — the gap persists even in patients on weight-neutral agents like metformin or weight-losing SGLT2 inhibitors, so background medications explain only part of it.
5. Harder-to-move population baseline. Diabetics tend to have longer-standing obesity, older age, more sarcopenic/metabolically defended physiology, lower exercise capacity, and possibly a distinct gut microbiome and genetic predisposition — all of which independently blunt weight-loss responses regardless of drug class.
Unfortunately, the truth is no one has any idea why this is. But it does make for interesting reading
David Rosenstein MD